Blog

Financial graph overlay on city skyline with upward trend and growth arrows.

General HealthTech Valuations in Europe (2025)The European healthtech M&amp;A market has been active in 2025, with a notable increase in deal volume and value. While the overall trend is positive, valuations are becoming more selective, with a strong emphasis on profitability, proven business models, and strategic value.Average Revenue Multiples (EV/Revenue): The average revenue multiple for general healthtech companies in Europe is typically in the range of 4x-6x. Some reports from Q1 2025 cited a more precise average of 4.8x.Average EBITDA Multiples (EV/EBITDA): For healthtech companies with positive earnings, the enterprise value to EBITDA multiple is generally observed between 10x-14x, a slight increase from the 2024 range.Digital Therapeutics (DTx) Specific Trends and Multiples Digital therapeutics, as a specialized and high-growth sub-sector of healthtech, can command premium valuations, especially for companies with certain characteristics.Premium for AI and Innovation: Companies with proprietary AI solutions, robust data platforms, or those adjacent to the biotech sector are attracting heightened interest. These firms can see multiples rise to 6x-8x revenueor even higher, well above the sector average. This premium reflects a buyer's willingness to invest in technology that delivers measurable cost savings and improved patient outcomes.Focus on Clinical Validation and Reimbursement: The market is maturing, and investors are demanding more than just a good idea. They are looking for companies with:Clinically proven datasets. Clear regulatory and reimbursement pathways.Defensible business models, often linked to value-based care.Shift to Value-Based Care: Digital therapeutics that enable a shift from fee-for-service to value-based care are particularly attractive. Solutions for chronic disease management and population health analytics are gaining traction with payers and providers, and these companies can see multiples climb to 5.5x-7x revenue.M&amp;A Activity and "Selective Scale": The first half of 2025 has seen a trend of "selective scale" in the digital health sector. While overall funding has declined, the average deal size for late-stage financings has increased. This signals a global reallocation of capital towards more substantial, proven investments rather than a broad, speculative approach. M&amp;A activity is largely driven by consolidation, with larger entities acquiring smaller, specialized firms to broaden their portfolios.Market Context and DriversSeveral factors are shaping the valuation landscape in 2025:AI Integration: Artificial intelligence is a primary driver of valuation, as firms with proprietary AI algorithms for diagnostics, drug discovery, or patient care are seeing heightened interest.Regulatory Clarity: In Europe, regulatory bodies like the EMA are refining frameworks for digital health tools, which boosts investor confidence and can lead to a lift in multiples for compliant firms.Chronic Disease Management: The rising prevalence of chronic conditions like diabetes and obesity is creating a strong demand for effective digital health interventions, making this a key growth area.Private Equity Interest: Private equity firms are increasingly active in the European healthtech space, competing with strategic buyers for attractive assets. This is driving up competition and, in some cases, valuations for high-quality companies.To discuss how Nelson Advisors can help your HealthTech, MedTech or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

HealthTech Valuations in Europe 2025 - Digital Therapeutics (DTx) Specific Trends and Multiples

HealthInvestor Power List 2025 Awards #HIPowerList25 &nbsp;&nbsp; Nelson Advisors Partner Lloyd Price has been invited to Judge the 'HealthInvestor Power List 2025 Awards' recognising the most effective, inspiring and influential leaders in Health and Social Care &nbsp;&nbsp; <a data-mce-href="https://healthinvestorpowerlist.com" href="https://healthinvestorpowerlist.com" title="https://healthinvestorpowerlist.com" target="_blank" rel="noopener">https://healthinvestorpowerlist.com</a> &nbsp;&nbsp; 'Our name change from HealthInvestor Power 50 to HealthInvestor Power List reflects our commitment to inclusivity and broader recognition within the industry, showcasing a diverse and comprehensive range of leaders and innovators.' &nbsp;&nbsp; With new categories and independently judged by a panel of industry experts, we can better acknowledge the dynamic and evolving landscape of our industry, celebrating excellence in a way that is both inclusive and representative of health investment. &nbsp;&nbsp; For nearly 15 years, we have celebrated the most effective, inspiring and influential leaders in health and social care. In 2025, we’re recognising the ever-evolving landscape of our industry with new categories, independently judged by a panel of experts, to celebrate excellence within the sector. Nexus Media GroupThe Awards are hosted by Nexus Media Group, a leading B2B publishing and events company for the health, social care, seniors housing, education, early years and property sectors.Nexus Media Group is a publishing and events company, which focuses on the health, education, early-years and property sectors. Our range of established media titles and sector-leading events provide market intelligence and business connections, underpinned by a long-standing commitment to editorial excellence.Established in 2004, our London-based team of journalists and sector experts provide insight and introductions to complex marketplaces.<a data-mce-href="https://nexusmediagroup.co.uk" href="https://nexusmediagroup.co.uk" title="https://nexusmediagroup.co.uk" target="_blank" rel="noopener">https://nexusmediagroup.co.uk</a>

Nelson Advisors to Judge the 'HealthInvestor Power List 2025' Awards #HIPowerList25

Healthcare, woman or nurse with tablet for research, medical info or diagnosis results with smile. Hospital, female physician and digital for report, online consultation and good news with telehealth

Beyond their role as innovators, nurses are the primary generators and curators of the data that fuels AI. Detailed nursing notes and observations captured in electronic medical records (EMRs) are critical for powering next-generation AI tools.&nbsp; &nbsp;&nbsp; For instance, Natural Language Processing (NLP) algorithms are being trained to analyse nursing triage notes to identify predictors for which Emergency Department patients are likely to be admitted to the hospital. This direct link between nursing documentation and AI's intelligence reinforces the central assertion of this report. Nurses are "strongly attuned to capturing the patient and nurse story through data".&nbsp; &nbsp;&nbsp; However, a key challenge exists: the data that AI models currently consume is an incomplete representation of the true nursing role. The "hidden complexities", the empathy, the subtle observations, the emotional support, are not easily documented in standardised charts. This creates a fundamental paradox in nursing data. The current datasets omit the most critical human-centric variables that define high-quality care. Consequently, the report concludes that for AI to be truly effective, the nursing role must expand beyond data generation to include shaping new data collection methods that capture these nuanced, holistic elements.To build trustworthy and effective AI, nurses must be involved at every stage of the development lifecycle, from the initial design through deployment and ongoing evaluation. Nurses have a professional responsibility to be knowledgeable about the data used to train AI models and to ensure transparency throughout the process. This necessitates interdisciplinary collaboration with data scientists, clinicians, and ethicists, which is crucial for creating innovative and ethically sound tools.&nbsp;The future of healthcare AI is not about a machine replacing a human, but about a symbiotic relationship where an intelligent tool works in concert with a compassionate professional. &nbsp;&nbsp; &nbsp;By freeing nurses from administrative burdens and augmenting their clinical judgment, AI can enhance their capacity to deliver the empathetic, human centred care that defines their profession.&nbsp;To discuss how Nelson Advisors can help your HealthTech, MedTech or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

Nurses as the Primary Data Source: Fuelling the Next Generation of AI Models

Digital innovation across the NHS in the next 12 months is not just about adopting new gadgets; it's a fundamental, system-wide transformation aimed at addressing key challenges like long waiting times, staff burnout, and the shift from treating sickness to preventing it. The NHS's recent "Fit for the Future: 10-Year Health Plan" and related strategies for 2024-2025 and beyond provide a clear roadmap for this change.Here are the key areas of digital innovation to watch in the next 12 months:1. Digital and Data-Driven Transformation This is the most prominent area of innovation and will be the foundation for many other changes. The NHS is moving decisively from an "analogue to digital" model.Single Patient Record (SPR): The development of a national, secure Single Patient Record is a top priority. This "patient passport" will unify a person's health data, including medical history, genomics, and data from wearables, giving clinicians a complete view of the patient and improving care coordination. The rollout of federated data platforms will support this effort. Expansion of the NHS App: The NHS App is being transformed into a "full front door to the entire NHS." Its functionality will be significantly expanded to allow patients to book appointments, communicate with professionals, receive advice, view care plans, and self-refer to services. A new "HealthStore" marketplace within the app will provide access to approved digital health apps and tools. Artificial Intelligence (AI): AI is a major focus for improving productivity and clinical decision-making. Key applications to watch include:Ambient AI Scribes: The widespread deployment of voice recognition technology to automate clinical notetaking and reduce administrative burdens for staff.AI-enabled Diagnostics: Using AI to analyze X-rays, scans, and other medical images to assist in faster and more accurate diagnoses, particularly in specialties like dermatology, ophthalmology, and cardiology. Automated Workflows: AI and automation will be used to streamline administrative tasks and optimize clinical pathways.2. Shifting Care from Hospitals to the CommunityThe NHS is committed to moving away from a hospital-centric model of care to one that is closer to people's homes, a shift from "hospital to community."Virtual Wards: The expansion of virtual wards (also known as "hospital at home") where patients receive acute care and monitoring in their own homes, supported by remote technology. Neighbourhood Health Centres: The establishment of "one-stop shop" health centres in communities, which will offer a range of patient care services and serve as the base for multidisciplinary teams. Enhanced Role of Community Pharmacy: Community pharmacies will take on a greater role in managing long-term conditions and will be integrated with the single patient record to provide more coordinated care.3. Focus on Prevention and Personalised CareThere is a strategic shift from treating sickness to preventing it, with a strong emphasis on proactive and personalized approaches.Genomics: The NHS is investing in genomic sequencing, including a project to sequence the genomes of newborns to build a database for understanding health risks and informing preventative measures. Wearables and Biosensors: The use of smart devices to continuously collect health data for monitoring chronic conditions, prevention, and post-acute treatment. This data will be integrated into the single patient record to enable more predictive care. Personal Health Budgets: The NHS aims to at least double the number of people offered a personal health budget, giving individuals more control and choice over their care. 4. Improving Clinical and Operational Efficiency Innovation is also focused on addressing systemic pressures like waiting times and workforce shortages.Simplified Procurement: The NHS is introducing new, more streamlined procurement processes, including a "NHS innovator passport for medtech," to speed up the adoption of new technologies. Elective Care Reforms: Technology will play a key role in reducing elective care waiting times, including through digital patient engagement and improved data access for clinicians. Staff Empowerment: Beyond AI scribes, the NHS is exploring other technologies to reduce the administrative burden on staff and free up clinical time. This includes digital tools that improve productivity and resource access.To discuss how Nelson Advisors can help your HealthTech, MedTech or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

Key areas of NHS digital innovation to watch in the next 12 months

Nelson Advisors Partner Lloyd Price has been invited to lead the 'HealthTech M&amp;A and IPOs Panel' at the Global Health Exhibition 2025 in Riyadh, Saudi Arabia. #GHE25 &nbsp;&nbsp; The Global Health Exhibition 2025 &nbsp;&nbsp; The Global Health Exhibition in Riyadh is a major event focused on healthcare innovation, investment, and transformation. It brings together global leaders from both the public and private sectors to discuss the future of healthcare. &nbsp;&nbsp; The exhibition features: &nbsp;&nbsp; Conferences: Including a Leaders Summit for high-level discussions, a Medical Excellence Forum, a Digital Health Forum, and a Venture Forum. Exhibition Floor: Showcasing the latest in healthcare technology, including digital health, AI, medical devices, and more. Networking: Opportunities for professionals, investors, and innovators to connect and explore partnerships. &nbsp;&nbsp; The event will take place from October 27-30, 2025, at the Riyadh Exhibition and Convention Center in Malham, Saudi Arabia.bringing together 1,000+ global presenters, 1,500+ exhibitors, and leading investors. &nbsp;&nbsp; The event capitalises on Saudi Arabia's dynamic healthcare market and its strategic position as a global investment hub. The event combines CME-accredited conferences, cutting-edge technology showcases, and exclusive investment forums, making it the definitive platform where healthcare innovation meets commercial opportunity in one of the world's most rapidly evolving markets. &nbsp;&nbsp; The Global Health Exhibition 2024The Global Health Exhibition in Saudi Arabia is a major annual event that has quickly grown to become a prominent platform for the healthcare industry, both regionally and globally. Here's a look at its history and development: &nbsp;&nbsp; Origins and Purpose &nbsp; The Global Health Exhibition was launched in 2018 under the patronage of the Saudi Ministry of Health. Its creation was a direct response to Saudi Arabia's ambitious Vision 2030 plan, which includes a significant focus on transforming and modernizing the country's healthcare sector. The exhibition was established to provide a business platform for local and international healthcare companies to connect with the Saudi market and contribute to the Kingdom's healthcare goals. &nbsp;&nbsp; The event is organized by Informa Life Sciences Exhibitions, which also manages other major healthcare events like Arab Health. &nbsp;&nbsp; Key Milestones and Growth &nbsp;&nbsp; First Edition (2018): The inaugural exhibition took place from September 10-12, 2018, at the Riyadh International Convention and Exhibition Center. It aimed to provide a platform for 10,000 attendees to engage with over 500 exhibiting companies. The event also featured a multi-disciplinary congress with a focus on topics like Healthcare Transformation, Investment, and Innovation.Rapid Expansion: The exhibition has seen remarkable growth in subsequent years, reflecting the significant investment and focus on healthcare in Saudi Arabia. The event has expanded in size, attendance, and the number of participating countries.Post-Pandemic Transformation: The 2023 and 2024 editions of the Global Health Exhibition marked a new, transformative phase. The event has become a key forum for global collaboration and has witnessed the signing of numerous agreements and partnerships in areas like pharmaceuticals, biotechnology, and digital health.2023 Edition: The 2023 exhibition, held from October 29-31, was themed "Invest in Health." It featured over 300 companies from 29 countries and focused on topics like preventive care, artificial intelligence, and biotechnology.2024 Edition: The 2024 edition, held from October 21-23, was also a major success. It reportedly drew over 105,000 visitors, with 72% of attendees being international. The event saw announced investments and deals exceeding SAR 50 billion (Saudi Riyals), including significant projects in pharmaceutical manufacturing and digital transformation. It was held at the Riyadh International Convention and Exhibition Center in Malham.The Future: The exhibition continues to grow. The 8th edition is scheduled for October 27-30, 2025, and is expected to be the largest yet, with a continued focus on "Invest in Health" and attracting a high level of international participation. &nbsp;&nbsp; Core Focus Areas &nbsp;&nbsp; The Global Health Exhibition is more than just a trade show; it's a comprehensive platform for industry development. Key focus areas have included: &nbsp;&nbsp; Vision 2030: The exhibition is a cornerstone of Saudi Arabia's Health Sector Transformation Program, showcasing progress and attracting investments to achieve the goals of Vision 2030.Investment and Partnerships: It serves as a crucial hub for attracting foreign investment and fostering partnerships between public and private sector entities, both local and international.Innovation and Technology: The event highlights cutting-edge medical technologies, including AI, digital health solutions, and biotechnology, that are transforming the healthcare landscape.Knowledge Exchange: Through its various forums and conferences (such as the Leaders' Summit, Medical Excellence Forum, and Digital Health Forum), the exhibition provides a platform for experts and policymakers to share knowledge and discuss best practices.To discuss how Nelson Advisors can help your HealthTech, MedTech or Digital Health company, or to schedule a meeting with Nelson Advisors at the Global Health Exhibition 2025 #GHE25 in Riyadh, Saudi Arabia, &nbsp;please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors to lead the 'HealthTech M&A and IPOs Panel' at the Global Health Exhibition 2025 #GHE25

AI powers big data analysis and automation workflows, showcasing neural networks and data streams for business. Artificial intelligence, machine learning, digital transformation and tech innovation.

Proprietary datasets have become a critical asset and a major source of competitive advantage in the healthtech industry. Unlike publicly available data, proprietary data is unique to a company, often collected through its own products, services, or partnerships. This exclusivity creates a powerful moat that is difficult for competitors to replicate.I. Value PropositionThe value proposition of proprietary data sets in healthtech is centered on their ability to create unique, high-quality, and actionable insights that improve health outcomes and reduce costs. This value is delivered to various stakeholders in the healthcare ecosystem:For Patients: Improved patient outcomes through personalized medicine, earlier disease diagnosis, and more effective treatment plans. Data from wearables, for example, can be used to provide real-time, continuous monitoring, and personalized health recommendations.For Healthcare Providers: Enhanced clinical decision-making through predictive analytics and AI-powered tools that identify at-risk patients, streamline workflows, and optimize resource allocation. Proprietary datasets can provide a more holistic view of a patient's health, including social determinants of health and lifestyle factors.For Payers and Insurers: The ability to reduce wasteful spending, predict and manage high-cost populations, and develop more effective value-based care models.For Life Sciences Companies (Pharma, Biotech): Accelerated drug discovery and development, faster clinical trial validation, and a deeper understanding of real-world evidence. This can lead to more targeted therapies and a higher success rate for new drugs.A strong value proposition is built on the unique benefits, cost savings, and differentiation a company's data offers compared to current practices. This is often backed by robust evidence and a clear demonstration of how the data addresses an unmet need.II. ValueThe value of proprietary healthtech data is multifaceted and can be quantified in several ways:Clinical Value: This is the most direct measure, showing how the data improves health outcomes. Examples include a diagnostic tool with a lower false positive rate, an algorithm that predicts disease progression, or a platform that improves medication adherence.Economic Value: This relates to cost savings and new revenue streams. The data can lead to reduced hospital readmissions, more efficient clinical trials, or the ability to offer premium pricing for a unique solution. Some estimates suggest that a single patient dataset can be worth hundreds or even thousands of dollars depending on its therapeutic focus and type.Operational Value: This includes improvements in efficiency, such as automating tasks, reducing administrative burdens, and optimizing hospital operations. Predictive analytics, for instance, can help healthcare organizations anticipate demand for services.Research Value: The data can be a valuable asset for research, driving new discoveries and fueling innovation in drug development and medical device creation. Companies can monetize this data through partnerships or by offering it to researchers. The value of a dataset is determined by several factors:Volume and Variety: A large and diverse dataset (e.g., combining claims, clinical, and social data) is more valuable for training powerful AI models.Uniqueness and Novelty: Data that is difficult for competitors to obtain, such as real-time streams from connected devices or rare genomic data, holds higher differentiation potential. Quality and Completeness: The data must be accurate, clean, and free from significant gaps.&nbsp; Context and Integration: Data that is well-contextualized and harmonized across different sources is more valuable for generating actionable insights.III. Strategic AdvantagesA proprietary data set is a powerful strategic asset that can create a sustainable competitive advantage, also known as a "data moat." This advantage is built on several key pillars:Defensible Competitive Moat: Unlike a patent, which eventually expires, a proprietary dataset can grow and become more valuable over time. As more data is collected, the company's algorithms and insights become more accurate, creating a self-reinforcing loop that is incredibly difficult for new entrants to replicate.Enhanced AI and Machine Learning Capabilities: Proprietary data is the essential fuel for developing and training superior AI models. Companies with unique datasets can build models that are more accurate, less biased, and better at addressing specific, high-value problems in healthcare. For example, a company that has trained a large language model (LLM) on thousands of healthcare entities and concepts can offer an AI assistant that is more accurate and less prone to "hallucinations" than a general-purpose model.Personalization and Customization: Unique data allows healthtech companies to build products and services that are highly personalized to individual patients, providers, or organizations. This leads to better engagement, improved outcomes, and stronger customer loyalty.New Product and Service Development: The insights derived from proprietary data can be the basis for entirely new product lines or business models. For instance, a company analyzing real-world evidence from its data could identify new therapeutic applications for an existing drug or pinpoint a previously unknown disease pattern.Increased Valuation and Attractiveness for M&amp;A: Companies with valuable, proprietary datasets are often more attractive to investors and potential acquirers. The data itself is a key asset that can be leveraged for future growth and innovation.In summary, proprietary datasets are not just a tool for healthtech companies; they are the foundation for building a defensible market position, creating outsized value for all stakeholders, and driving the future of healthcare innovation.To discuss how Nelson Advisors can help your HealthTech, MedTech or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

HealthTech Valuations in Europe 2025 - Digital Therapeuti...

Nelson Advisors to Judge the 'HealthInvestor Power List 2...

Nurses as the Primary Data Source: Fuelling the Next Gene...

Key areas of NHS digital innovation to watch in the next ...

Nelson Advisors to lead the 'HealthTech M&A and IPOs Pane...

Proprietary Datasets in HealthTech: Value Proposition and...